Engelsk titel: Natalizumab (Tysabri)
Läs online
Författare:
Ravnborg M
Email: mads.ravnborg@rh.hosp.dk
Språk: Dan
Antal referenser: 3
Dokumenttyp:
Artikel
UI-nummer: 07101353
Sammanfattning
Natalizumab is a humanized recombinant monoclonal antibody against a4 -intigrin. In a large phase III study on relapsing-remitting MS Natalizumab reduced the relapse rate by 68% and the appearance of permanent neurological deficits by 42%. Currently, Natalizumab is the most effective disease-modifying treatment of relapsing-remitting MS. The clinical use of the treatment will be restricted initially due to uncertainty about the risk of opportunistic infections in long term treatment.